An interventional study of AltaValve System. in Mitral Regurgitation, Mitral Insufficiency and Mitral Valve Incompetence, sponsored by 4C Medical Technologies, Inc.. Recruiting at 58 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.
Sponsored by 4C Medical Technologies, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 118 studies in Mitral Valve Insufficiency with a site in United States — 33 open to participants now, 53 under way, none of them phase 3. Mitral Valve Insufficiency · United States.
Among the 118 studies in Mitral Valve Insufficiency with a site in United States, this one is the 12th largest by planned enrollment of the 81 interventional ones that give a count, is one of 4 that started in 2024, is one of 64 with no phase, reaches primary completion later than 44 of the 52 other live ones, and was the 100th registered.
471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.
Browse Mitral Valve Insufficiency studies →33 of the 118 studies in Mitral Valve Insufficiency with a site in United States are open now. Recruiting first, the newest first:
Capstan Medical · Sites in United States
Ages 18+
Abbott Medical Devices · Sites in United States
Ages 18+
Polares Medical SA · Sites in United States
Ages 21+
InnovHeart · Sites in United States
Ages 18+
Nyra Medical, Inc. · Sites in United States
Ages 21+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
118 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 4 · Phase 4 4
First in 1992; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 450 is above the median of 69 across 280 interventional studies indexed under Mitral Valve Insufficiency.
Median enrollment 60 across the 81 interventional studies, 200 across the 37 observational. Of the 52 that completed or were terminated, 26 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
62 of 118 have an industry lead sponsor. The 10 most frequent:
4C Medical Technologies, Inc. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
4C Medical Technologies, Inc. has 2 studies filed under Mitral Valve Insufficiency — fewer than ten, so there is no comparison to draw.
13 of the studies in Mitral Valve Insufficiency with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04408430Mayra GuerreroThe MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves). | 2026-12 |
| NCT07655505Intuitive SurgicalUse of Force Feedback Instruments With the da Vinci Surgical System, Model IS5000 for Mitral Valve Repair | 2026-12-31 |
| NCT05061004Abbott Medical DevicesCephea Early Feasibility Study | 2026-12-31 |
| NCT03142152Cardiac Dimensions, Inc.The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR | 2026-12-31 |
| NCT06738615Atlantic Health SystemAssessing the Relationship Between Symptoms and Mitral Regurgitnant. Severity | 2027-01-02 |
Add all 13 to your calendar (.ics) → With an account.
Among the 118 studies in Mitral Valve Insufficiency with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, single arm, multicenter, clinical trial designed to evaluate the safety and performance of the AltaValve System for the treatment of mitral regurgitation in a targeted patient population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria (Abbreviated List):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Designed to evaluate the safety and performance of the AltaValve System for the treatment of moderate-to-severe or severe MR in a targeted patient population without at least moderate mitral annular calcification (MAC).
Device: AltaValve System.
Designed to evaluate the safety and performance of the AltaValve System for the treatment of moderate-to-severe or severe MR in a targeted patient population with moderate to severe MAC.
Device: AltaValve System.
Transcatheter Mitral Valve Replacement.
Composite of all-cause mortality or heart failure hospitalization.
Time frame: 12 months.
All-cause mortality, disabling stroke, acute kidney injury (stage 3 or with renal replacement), mitral valve re-intervention (surgical or transcatheter), major bleeding requiring intervention.
Composite.
Time frame: 30 Days or hospital discharge (whichever is longer).
Technical success.
Technical success will be considered achieve when all of the following are present: * Successful application of the delivery system as intended. * Successful device placement. * Reduction in mitral regurgitation grade to ≤ 2+.
Time frame: Day 0.
Mitral valve re-intervention.
Mitral valve re-intervention after index procedure
Time frame: At 30 days, 6 months, 1 year, and annually thereafter for up to 5 years.
Changes in Kansas City Cardiomyopathy Questionnaire (KCCQ).
Quality of life improvement.
Time frame: 6 months and 1 year.
Changes in Six-minute walk test (6MWT).
Quality of life improvement.
Time frame: 6 months and 1 year.
New pacemaker rate.
Time frame: 1 month, 6 months and 1 year.
Started Sep 2024 (actual). Primary completion is estimated for Sep 2029, 60 months after the start.
Of 91 industry-sponsored interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 144. This study's planned 60 months is close to that.
Counting every sponsor, half of 144 studies reached it within 56 months; a quarter within 25 and three quarters within 108.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
4C Medical Technologies, Inc.